I've coordinated medical supply orders at a 400-bed hospital for nine years. In that time, I've handled over 300 rush requests—same-day deliveries, overnight shipping, urgent vendor calls at 5 PM on a Friday. Here's the uncomfortable truth I've learned: most of those emergencies were preventable.
That's not a knock on our clinical staff. They're working under constant pressure. The problem is systemic: hospitals keep buying products to respond to complications instead of buying the right products to prevent them in the first place. And that's a more expensive way to run a hospital.
Prevention isn't a cost center—it's the cheapest investment a hospital can make. The sooner supply chains treat it that way, the better for patients, for clinicians, and for budgets.
One Pressure Injury, Three Months of Treatment
In March 2024, I got a call from one of our step-down units. A patient had developed a pressure injury that wasn't healing with basic care. They needed a specialty dressing delivered the same day. We paid $260 in overnight shipping on top of the product cost.
That patient ended up in treatment for three months. I don't have the exact final numbers—that stays with our finance team—but the hospital stay alone was well into five figures. The Agency for Healthcare Research and Quality (AHRQ) estimates hospital-acquired pressure injuries cost $9,000 to $60,000 per occurrence (Source: AHRQ, 2023; costs vary, verify current figures). The numbers I've seen internally match that range.
Here's the frustrating part: three weeks before that call, a nurse had requested extra supplies for this exact patient. She'd flagged the patient as high-risk. The request sat in budget review. The pressure injury developed while we were still deciding whether to spend $85 on preventive dressings.
The dressing we eventually ordered overnight was from Mölnlycke's Mepilex® family. A box costs our hospital around $85, give or take. The kind of thing that should have been in the supply room already. Was it an exotic product? No. It's a standard dressing in many hospitals. It was just tied up in an approval process that valued paperwork over patient need.
Skipping an $85 preventive purchase to avoid straining the budget cost us thousands in treatment. I still kick myself when I think about how avoidable that was.
The Safetac® Difference: Trust Is a Supply Chain Factor
I'm not a wound care specialist, so I can't fully explain the science behind modern dressings. What I can tell you, from a supply chain perspective, is that trust matters in product usage. When a box arrives with the Mölnlycke logo on it, our staff knows what they're getting. They recognize the Safetac® silicone adhesive technology. They know how the dressing behaves, how it removes, and how it interacts with fragile skin. That familiarity isn't a nice-to-have—it determines whether staff use the product correctly. And correct use is a form of prevention.
Our hospital has standardized on several Mölnlycke Health Care US products over the years, in wound care and surgical services. That standardization didn't happen by accident. It happened because clinicians requested it, and because we saw fewer substitution problems when staff knew exactly what they'd find on the shelf.
Prevention is a chain: the right product, the right protocol, the right training, the right inventory. Break any link—a late order, a substituted product, a stockout—and the system fails.
The Same Pattern, Across Different Care Areas
This prevention-first mindset isn't unique to wound care. I've seen the same logic play out across other departments:
- Ostomy care: The ostomy bag is what patients see, but the skin barrier underneath is where prevention succeeds or fails. When the right barrier is stocked and applied, peristomal skin stays intact. When it's compromised, patients develop denuded skin that requires specialist consults and extended follow-up. We've seen this pattern enough times that our ostomy nurse now keeps multiple barrier sizes stocked on every floor.
- Catheter care: A surgical catheter is a routine device, but it's also one of the most common pathways for healthcare-associated infection. The Centers for Disease Control and Prevention (CDC) has published data showing catheter-associated urinary tract infections (CAUTIs) are among the most common hospital-acquired infections (Source: CDC, cdc.gov; verify current data). Prevention here depends on proper securement, consistent care protocols, and having the right supplies in stock. We carry securement kits on every unit now—it took one too many tape-and-tube setups to make that change.
- Diagnostics: You might be wondering, what is medical imaging's role in prevention? The textbook answer: imaging uses X-rays, CT, MRI, and ultrasound to see inside the body. The practical answer: early detection. But imaging only works when clinicians can act on what they see. That means having biopsy supplies, topical treatments, dressings, and even surgical readiness available once an image reveals a problem. The supply chain is what turns a finding into an action.
Three areas. Three different product categories. Same underlying principle: spend a little on the front end, save a lot on the back end.
The Hidden Cost of Being Reactionary
In the second quarter of 2024, I pulled the numbers on our urgent supply orders. There were 27 of them. Average extra cost—shipping, rush fees, and emergency vendor premiums—was around $400 per order. That's roughly $10,800 for the quarter, almost $43,000 a year on emergency delivery costs alone, simply because needed products weren't in stock.
And that number doesn't include the clinical consequences of delays. Every day a patient waits for the right dressing or the right barrier is a day a wound can worsen. Those consequences don't show up on a procurement spreadsheet, but they show up in length-of-stay, treatment costs, and patient outcomes.
I don't have hard data on what percentage of our urgent orders directly resulted in worse outcomes. What I can say, anecdotally, is that the worst cases I've been involved with were all cases where the right product was ordered days after it was needed—not before.
What Changed When We Started Taking Prevention Seriously
In mid-2024, in the months after that pressure injury case, our hospital made an intentional shift. We expanded our inventory of preventive products—advanced dressings, skin barriers, securement devices—and created a category for "clinically urgent standing supply." If a product was requested for a patient at high risk, the order bypassed the standard budget-review queue.
It took a few months for the effects to show. By Q4 2024, urgent orders had dropped from 27 per quarter to 11 per quarter. (Wait—27 to 11 per quarter, not per month. I always mix that up.) Rush fees were down about 60%. Patient-facing staff told us they spent less time chasing products and more time providing care.
Were all urgent orders eliminated? No. Some emergencies are genuinely unavoidable. But the avoidable ones—stockouts, budget-review delays, substitution errors—became noticeably rarer.
So, About That Supply Budget Review...
I can't speak to your hospital's specific financial situation. But I can tell you what 300+ urgent orders taught me: prevention supplies are not an optional extra. They're the cheapest insurance a hospital can buy.
The products that prevent wounds—high-quality dressings, skin barriers, securement devices—are evidence-based. They've been studied, published, and tested in thousands of clinical settings. Mölnlycke's portfolio, for example, is built around clinical evidence showing that better protection reduces tissue damage and supports healing. But a product that's never on the shelf can't protect anyone.
So here's my advice to supply leaders: start tracking the true cost of urgency. Every rush fee, every emergency order, every stockout-triggered substitution. You might find, as we did, that you're already paying a hidden premium—and that redirecting it toward preventive inventory is the best trade you'll make all year.
Prevention is better than cure for a simple reason: when prevention works, you don't need a cure. The products exist. The protocols exist. The evidence exists. The only remaining question is whether they're on the shelf when patients need them.
Let's make sure they are.
